세포 치료 및 유전자 치료 임상시험 시장 규모, 점유율 및 성장 분석 : 치료법별, 단계별, 적응증별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Cell And Gene Therapy Clinical Trials Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 9.76 Billion in 2025 to USD 28.85 Billion by 2033, growing at a CAGR of 14.52% during the forecast period (2026-2033).

The global market for cell and gene therapy clinical trials is fueled by rapid scientific advancements that have converted theoretical concepts into validated therapies. These trials focus on utilizing living cells and genetic materials to cure or prevent diseases rather than merely alleviating symptoms, addressing critical unmet medical needs in oncology, rare genetic disorders, and immunology. Significant growth in this sector is largely driven by improved manufacturing capabilities, which streamline supply chains and enhance production reliability. Standardization in vector yields and processing methods allows for increased clinical material availability for multicenter studies, fostering various treatment explorations. Additionally, strategic collaborations among biopharmaceutical firms, contract manufacturers, and healthcare institutions are expanding, reflected in rising investments that promote rapid enrollment and enhance the market potential for innovative therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell And Gene Therapy Clinical Trials market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell And Gene Therapy Clinical Trials Market Segments Analysis

Global cell and gene therapy clinical trials market is segmented by therapy type, phase, indication, end-user and region. Based on therapy type, the market is segmented into Cell Therapy and Gene Therapy. Based on phase, the market is segmented into Phase I, Phase II and Phase III. Based on indication, the market is segmented into Oncology, Rare Diseases and Neurological. Based on end-user, the market is segmented into CROs, Academic Medical Centers and Pharma & Biotech. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cell And Gene Therapy Clinical Trials Market

The Global Cell And Gene Therapy Clinical Trials market is significantly driven by recent advancements in vector development and delivery techniques, as well as innovative formulations that enhance the precision of cell targeting. These improvements help minimize adverse effects on surrounding cells while bolstering confidence in the manufacturing processes. Moreover, streamlined dosing methods contribute to the reliability of the therapeutic products, enabling more efficient protocols and improving patient recruitment for clinical trials. Additionally, advancements in the manufacturing and stability of these agents reduce operational challenges for sponsors, which in turn facilitates a greater number of clinical trials across diverse applications.

Restraints in the Global Cell And Gene Therapy Clinical Trials Market

The complexities involved in producing both autologous and allogeneic cell therapies pose significant challenges within the Global Cell and Gene Therapy Clinical Trials market. Maintaining high quality control standards and ensuring an effective cold-chain infrastructure are essential to preserving product integrity, yet they also restrict the volume of clinical studies conducted. These production hurdles demand specialized facilities, validated processes, and well-trained personnel to guarantee the safety and consistency of cell products. As a result, sponsors struggle to scale up trial participant enrollment across various sites, introducing operational risks that ultimately hinder the acceleration of trial approvals.

Market Trends of the Global Cell And Gene Therapy Clinical Trials Market

The Global Cell and Gene Therapy Clinical Trials market is witnessing a notable trend towards diversifying development platforms to enhance treatment options and reduce reliance on singular methodologies. Developers are expanding both vector and cellular approaches, facilitating the establishment of strategic partnerships that support modular process development. This diversification not only spurs flexibility in trial designs but accelerates the transition from research to clinical applications. By optimizing patient recruitment and minimizing program-level risks through adaptable platform stacks, firms can better align with regulatory demands. This ongoing evolution is expected to bolster market growth, attract new service providers, and fortify the resilience of therapeutic portfolios in a dynamic scientific and commercial environment.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Cell And Gene Therapy Clinical Trials Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Cell Therapy
  • CAR-T Cell Therapy
  • NK Cell Therapy
  • Stem Cell Therapy
• Gene Therapy
  • In Vivo Gene Therapy
  • Ex Vivo Gene Therapy

Global Cell And Gene Therapy Clinical Trials Market Size by Phase & CAGR (2026-2033)

• Market Overview
• Phase I
• Phase II
• Phase III

Global Cell And Gene Therapy Clinical Trials Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Oncology
• Rare Diseases
• Neurological

Global Cell And Gene Therapy Clinical Trials Market Size by End-User & CAGR (2026-2033)

• Market Overview
• CROs
• Academic Medical Centers
• Pharma & Biotech

Global Cell And Gene Therapy Clinical Trials Market Size & CAGR (2026-2033)

• North America (Therapy Type, Phase, Indication, End-User)
  • US
  • Canada
• Europe (Therapy Type, Phase, Indication, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Phase, Indication, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Phase, Indication, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Phase, Indication, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis AG (Kymriah)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (Yescarta)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (Abecma)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spark Therapeutics (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• uniQure NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sarepta Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (BMS)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcus Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Marker Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellular Biomedicine Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations